The big news continues to be the hangover effect from the Clovis Oncology Inc (NASDAQ:CLVS)’s presentation at the American Society of Clinical Oncology’s annual meeting on CO-1686, its investigational non-small cell lung cancer drug designed to target T790M-positive mutation. The initial data looked very promising, with estimated median progression-free survival in excess of 12 months, according to its press release. However, it was also noted by CEO Pat Mahaffay in discussions with analysts over the weekend that a couple of CO-1686 patients had to be placed on insulin after bouts of hyperglycemia. There are now obvious safety concerns surrounding CO-1686, which investors don’t believe Mahaffay addressed. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -26.17%. On last trading day company shares ended up $38.23. Analysts mean target price for the company is $98.63. distance from 50-day simple moving average (SMA50) is-34.71 %.
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, updated its drug development progress Lexicon Pharmaceuticals ,Inc (NASDAQ:LXRX) shares advanced 3.17% in last trading session and ended the day on $1.30. Gross Margin is % and its return on assets is -33.50 %. quarterly performance is -30.11%.
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for OGXI broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares moved down -6.06% in last trading session and was closed at $3.41, while trading in range of $3.39-$3.68. year to date (YTD) performance is -59.11%.
The analysts wrote, “Biota Pharmaceuticals (NASDAQ:BOTA) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.”Biota Pharmaceuticals Inc (NASDAQ:BOTA) ended the last trading day at $2.46. Company weekly volatility is calculated as 6.20% and price to cash ratio as1.68 . showed a negative weekly performance of -12.14%.
Onconova Therapeutics, Inc (NASDAQ:ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer.Onconova Therapeutics Inc (NASDAQ:ONTX) weekly performance is -10.27%. On last trading day company shares ended up $4.37. Analysts mean target price for the company is $11.50. distance from 50-day simple moving average (SMA50) is -22.18%.
Leave a Reply